An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs.
"None of these drugs are perfect," said a Glaxo senior VP. The FDA, which is not obliged to follow its panel's advice, has not come to any conclusion about whether the drug will be recalled. It has, however, proposed adding more prominent warning labels and even drawing up a patient registry. (Read more Avandia stories.)